Src-family protein tyrosine kinases: a promising target for treating chronic pain by Ge, Meng-Meng et al.




Src-family protein tyrosine kinases: A promising target for treating chronic
pain
Meng-Meng Gea, Ya-Qun Zhoua, Xue-Bi Tiana, Anne Manyandec, Yu-Ke Tiana, Da-Wei Yeb,
Hui Yanga,*
a Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
b Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
c School of Human and Social Sciences, University of West London, London, UK
A R T I C L E I N F O
Keywords:
Chronic pain
Src-family protein tyrosine kinases
N-methyl-D-aspartic acid receptor
Microglia
A B S T R A C T
Despite the growing knowledge of the mechanisms of chronic pain, the treatment of this disorder in the clinic
remains a major challenge. Src-family protein tyrosine kinases (SFKs), a group of non-receptor protein tyrosine
kinases, have been implicated in neuronal development and synaptic plasticity. SFKs are critical for the regulate
of N-methyl-D-aspartic acid receptor (NMDAR) 2B subunit phosphorylation by various transmembrane re-
ceptors, e.g., G-protein coupled receptors (GPCRs), EphB receptors (EphBRs), increased intracellular calcium,
epidermal growth factor (EGF) and other growth factors, and thus contribute to the development of chronic pain.
SFKs have also been regarded as important points of convergence of intracellular signalling components for the
regulation of microglial functions and the immune response. Additionally, the intrathecal administration of SFK
inhibitors signiﬁcantly alleviates mechanical allodynia in diﬀerent chronic pain models. Here, we reviewed the
current evidence for the role of SFKs in the development of chronic pain caused by complete Freund's adjuvant
(CFA) injection, peripheral nerve injury (PNI), streptozotocin (STZ) injection and bone metastasis. Moreover, the
role of SFKs in the development of morphine tolerance is also discussed. The regulation of SFKs therefore has
emerged as a potential therapeutic target for the treatment of chronic pain in terms of safety and eﬃcacy.
1. Introduction
Chronic pain is a major public health issue, and is generally cate-
gorized as cancer pain or chronic non-cancer pain, including in-
ﬂammatory pain, neuropathic pain and idiopathic/dysfunctional pain
[1]. The current clinical therapeutic strategies for chronic pain are in-
eﬀective because of their limited eﬀ ;ects or their various unwanted side
eﬀects [2,3]. Unfortunately, despite decades of eﬀorts, few eﬀective
analgesic treatments have been developed, and treating chronic pain
remains a major clinical challenge [4]. Therefore, it is crucial to provide
a better understanding of the cellular and molecular mechanisms of
chronic pain.
Src-family protein tyrosine kinases (SFKs), a group of non-receptor
protein tyrosine kinases, have been implicated in neuronal develop-
ment and synaptic plasticity [5,6]. There are at least nine members of
this family, namely: Src, Lck, Hck, Blk, Fyn, Lyn, Fgr, Yes and Yrk,
which share a modular structure comprising unique Src homology 2
(SH2), Src homology3 (SH3) and kinase catalytic domains [7,8]. It has
been reported that at least ﬁve SFK members, Src, Fyn, Lck, Yes and Lyn
are ubiquitously expressed in the central nervous system (CNS)
[6,9–11]. However, Blk, Hck and Fgr are only expressed in speciﬁc
tissues (Table 1) [7,12]. The activation of SFKs is strictly regulated by
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the phosphorylation and dephosphorylation of tyrosine residues [6,13].
Recently, a number of studies have demonstrated that aberrant SFK
activity may be a key element in the development of chronic pain. Here,
we reviewed the current evidence for the role of SFKs in the develop-
ment of chronic pain caused by complete Freund's adjuvant (CFA) in-
jection, peripheral nerve injury (PNI), streptozotocin (STZ) injection
and bone metastasis. Moreover, the role of SFKs in the development of
morphine tolerance is also discussed.
2. Possible mechanisms of SFKs in pain processing
Convincing evidence has shown that the activation of spinal N-
methyl-D-aspartic acid receptors (NMDARs) is implicated in neuronal
sensitization in chronic pain [14,15]. An array of transmembrane re-
ceptors (e.g., G-protein coupled receptors (GPCRs), EphB receptors
(EphBRs), increase intracellular calcium and the epidermal growth
factor (EGF)) which may cause robust SFKs activation within the
NMDAR in the spinal cord, leading to pain hypersensitivity [7,16]. Of
the ﬁve SFK members expressed in the CNS, Src and Fyn are known to
catalyse NMDARs by phosphorylating GluN2B at Tyr1472 [17,18]. The
intrathecal application of broad-spectrum SFK inhibitors potently pre-
vents phosphorylation-mediated enhancement of the NMDAR 2B sub-
unit as well as chronic pain [14,19].
SFKs are also considered key points of convergence of various in-
tracellular signalling components for the regulation of the immune re-
sponse and microglial functions (Fig. 1) [6,20,21]. Microglia are in-
volved in both the innate and adaptive immune responses in the CNS
[22]. In addition, our previous studies have demonstrated that micro-
glia are activated in the spinal cord in cancer pain [23,24]. Many lines
of studies have indicated that peri-sciatically administered interleukin
(IL)-1β or tumor necrosis factor (TNF)-α may be up stream of SFKs
activation under both physiological and pathological conditions
[21,25]. SFKs are considered to be crucial activators of toll-like re-
ceptors (TLRs), and thus play an important role in regulating the
activation of nuclear factor (NF)-κB and overexpression of pro-in-
ﬂammatory cytokines (e.g., IL-1β, TNF-α, IL-6) [5,26]. Positive feed-
back mediated by an autocrine mechanism contributes to the devel-
opment of chronic pain [25]. In addition, the intrathecal administration
of SFK inhibitors may reduce the expression of these cytokines. Mi-
togen-activated protein kinases (MAPKs), which are mainly activated in
the microglia, have been shown to be associated with the pathogenesis
of chronic pain [20]. SFKs are vital intermediates for various signalling
pathways and lead to the activation of MAPKs and the downstream
extracellular signal-related kinase (ERK) to mediate pathological pain
status [27–29]. As demonstrated by Li et al., the peri-sciatic adminis-
tration of recombinant TNF-α into the sciatic nerve of adult rats may
trigger positive feedback in the spinal cord, and ultimately induce the
overexpression of cytokines after SFK/MAPK activation [27]. These
cytokines may control the direction of plastic changes at C-ﬁbre sy-
napses, contributing to peripheral sensitization in the spinal cord [30].
Moreover, pretreatment with the SFK inhibitor PP2 reversed MAPK
activation in spinal microglia as well as mechanical allodynia induced
by recombinant TNF-α injection.
3. The role of SFKs in chronic pain and morphine tolerance
3.1. SFKs and inﬂammatory pain
Inﬂammation serves as a defensive barrier during innate immune
responses, triggered by physical injury or infection with bacteria,
viruses, or fungi [26]. Inﬂammatory pain is associated with maladap-
tive plastic changes and the activation of immune cells in the peripheral
or central nociceptive networks [31]. Transcription factors, such as NF-
κB, and a variety of inﬂammation genes, inducing inducible nitric oxide
synthase (iNOS), TNF-α and cyclooxygenase (COX)-2, are involved in
the inﬂammatory process [32]. As shown by Igwe et al., treatment with
wt-NF-κB double stranded oligodeoxynucleotides suppresses c-Src and
CFA-induced COX-2 expression in dorsal root ganglia (DRG) neurons,
Table 1
Fundamental characteristics of Src-family protein tyrosine kinases.





Src CNS (arcuate nucleus)
neurons, platelets,
osteoclasts
Tumor development, progression, resistance
to therapeutic agents, neuronal development,
synaptic plasticity
PDGF, other growth factors, EGF, IL-1β,
EphrinB2, GPCR,
intracellular calcium
NMDAR, MOR [6,7], [12], [17]
[56],
Fyn FynB: CNS;
FynT: cells of hematopoietic
origin
Cell growth, survival, adhesion, myelination,
cytoskeletal remodeling, motility,
axon guidance,








Yes CNS Neuronal development,
synaptic plasticity,
anti-tubulin agents
CDK1 PI3K/AKT [9,10] [12],





Antigens, CD14 P2X4R, PI3K [6] [32],








Hck hematopoietic cells Integrin signaling,
actin rearrangement,
LPS-initiated signaling
Integrin signaling in polymorphonuclear
leukocytes, CD14,m
onocyte chemotaxis, EGF




Cell migration, diﬀerentiation GPCR Chemokines production [8]
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-subtype glutamate receptor; BCAR1: breast cancer anti-estrogen resistance 1; CNS: central nervous
system; CD14: Lipopolysaccharide receptor; CDK1: cyclin-dependent kinase 1; EGF: epidermal growth factor; FAK: focal adhesion kinase; GPCR: G-protein coupled
receptor; HGF/MET: hepatocyte growth factor/hepatocyte growth factor receptor; IL-1β: interleukin-1 beta; ITK:interleukin-2 tyrosine kinase; LPS: lipopoly-
saccharide; MOR: μ-opioid receptors; NMDAR: N-methyl-D-aspartate receptor; NK cells: natural killer cells; PDGF: Platelet derived growth factor; PI3K:
Phosphoinositide 3-kinase; PKB/Akt: protein kinase B; PKC: protein kinase C; P2X4R: P2X4 receptor; TCR signaling: T cell receptor signaling.
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suggesting that Src activation is involved in NF-κB activation [33]. A
very recent study found that phosphorylation levels of Src is an up-
stream regulatory molecule of NF-κB. Moreover, Momordica cochinchi-
nensis Spreng, also known as gac or red melon, can reduce the pro-
duction of NF-κB, iNOS and COX-2 in LPS-activated RAW264.7 cells by
directly inhibiting Src/Syk activation [26]. Hence, the c-Src/NF-κB in-
teraction may represent an alternative therapeutic target for the treat-
ment of inﬂammatory pain.
Previous studies have shown that the phosphorylation of the
NMDAR 2B subunit by Src or Fyn served as a key step in enhancing
NMDAR 2B subunit function in the spinal cord after the intradermal
injection of CFA [16,34]. Various transmembrane receptors such as
GPCR/protein kinase A (PKA), GPCR/protein kinase C (PKC), and
EphBRs are involved in this process [16,35,36]. Furthermore, the in-
trathecal administration of the Src inhibitor PP2 delays the onset of
CFA-induced mechanical allodynia [35]. In addition to spinal me-
chanisms, supraspinal mechanisms appear to be involved in the role of
Src in pain transmission. As reported by Xu et al., CFA-treatment en-
hances the spontaneous ﬁring of arcuate nucleus (ARC) neurons, which
is suppressed by the NMDAR antagonist Ro25-6981 and the Src in-
hibitor PP2 [14]. This ﬁnding suggests that ARC Src/GluN2BR activa-
tion may contribute to inﬂammatory pain.
3.2. SFKs and neuropathic pain
Neuropathic pain refers to the aberrant functioning of a pathologi-
cally altered in the CNS [6]. The hallmarks of neuropathic pain are
enhanced sensitivity to noxious stimuli (hyperalgesia) and abnormal
pain responses to innocuous stimuli (tactile allodynia) [37,38]. Despite
increasing knowledge of the mechanisms of chronic pain, the treatment
of neuropathic pain remains a major challenge in clinical practice [1].
Various animal models, such as models of PNI-, diabetes-, spinal cord
injury (SCI)- and chemotherapy-induced pain, have been established to
study the mechanisms of neuropathic pain of diﬀerent aetiologies
[1,38]. Recently, a growing body of evidence has indicated that SFKs
play a critical role in neuropathic pain caused by PNI and diabetes
(Fig. 2) [18,39].
3.2.1. SFKs and peripheral nerve injury
PNI causes aberrant excitability in the CNS, notably in the primary
sensory ganglia and the spinal cord [38]. This pathological alteration of
nociceptive transmission requires interactions between microglia and
other cell types [40]. After PNI, resting microglia are activated through
a series of molecular changes. Tsuda et al. indicated that stimulation of
the IFN-γ receptor (IFN-γR) in naïve rats activates spinal microglia and
produces long-lasting pain hypersensitivity. Conversely, ablating IFN-
γR signiﬁcantly impairs nerve injury-evoked microglial activation and
mechanical allodynia. They also found that IFN-γ-stimulated spinal
microglia can upregulate Lyn and the P2X4 receptors (P2X4Rs) [38].
Furthermore, Lyn-deﬁcient mice also show suppressed microglial acti-
vation in the spinal cord, indicating that Lyn is involved in the mole-
cular changes that underlie microglial activation [6]. Activated spinal
microglia also released various pro-inﬂammatory cytokines, chemo-
kines and neurotrophic factors that regulate pain transmission [41].
Fig. 1. The role of SFKs in regulating microglial functions and the immune response. SFKs are considered crucial activators of TLR, playing a crucial role in regulating
the activation of NF-κB and the overexpression of pro-inﬂammatory cytokines (e.g., IL-1β, IL-6, and TNF-α), which can amplify neuronal excitability and facilitate
nociceptive transmission through interactions between microglia and other cell types in the spinal cord. Various intracellular signalling cascades, including the SFK/
MAPK and SFK/ERK pathways, are known to play a crucial role in mediating the functions of microglial activity. BDNF: brain-derived neurotrophic factor; EP-1R:
prostaglandin receptor; ERK: extracellular signal-related kinase; IL-1β: interleukin-1β; IL-1R: interleukin-1 receptor; IL-6: interleukin-6; IL-18: interleukin-18; IL-18R:
interleukin-18 receptor; MAPK: mitogen-activated protein kinases; NF-κB: nuclear factor-κB; PGE2: prostaglandin 2; P2X4R: P2X4 receptor; SFKs: Src-family protein
tyrosine kinases; TNF-α: tumor necrosis factor-α; TNF-αR: tumor necrosis factor-α receptor; TLR: toll-like receptor.
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Brain-derived neurotrophic factor (BDNF), a classical neurotrophic
factor released by spinal microglia, is a major driver that disrupts the
balance between synaptic excitation and inhibition by mediating
phosphorylation of the GluN2B-NMDAR via Fyn after PNI [42,43].
Moreover, In a vitro experiment, it was shown that treatment with
BDNF increases NMDAR currents in cultured DRG neurons and that this
eﬀect is reversed by a BDNF scavenger, a TrkB receptor antagonist and
SFK inhibitors (PP2 and SU6656) [44]. Despite abundant evidence of
the crucial role of NMDAR activation in the spinal cord in the devel-
opment of neuropathic pain, little is known about the supraspinal me-
chanisms associated with the activation of NMDARs. It has been sug-
gested that the activation of SFKs/NMDARs in the insular cortex may
have a potential role in the regulation of pain transmission [15]. In this
study, it was shown that the insular cortex shows changes in synaptic
plasticity, that are associated with increases in long-term potentiation
(LTP) in the amount of NMDARs after common peroneal nerve (CPN)
ligation. Moreover, the activation of adenylyl cyclase subtype 1 (AC1)/
PKA/Src was reported to be involved in the modulation of synaptic
NMDARs in the insular cortex.
Glial cell line-derived neurotrophic factor (GDNF), a member of the
transforming growth factor-β superfamily, has been shown to be in-
volved in various biological processes, such as the development, sur-
vival, and maintenance of neurons in the CNS [45]. Treatment with
GDNF can signiﬁcantly relieve chronic constrictive injury (CCI)-in-
duced mechanical allodynia, and the associated mechanism may the
direct or indirect regulation of nectin-1/c-src signalling [46]. These
ﬁndings might provide new targets for the treatment of neuropathic
pain.
3.2.2. SFKs and diabetic neuropathy
Neuropathy, one of the most common complications of diabetes,
remains an unsolved clinical problem [47]. It is often resistant to cur-
rent analgesics because of the cellular and molecular mechanisms of
diabetic neuropathy are largely unknown. Previous studies have de-
monstrated that increased NMDAR activity signiﬁcantly contributes to
central sensitization in diabetic neuropathy [47,48]. Protein tyrosine
phosphatase 1B (PTP1B), a ubiquitous enzyme, has been shown to sti-
mulate Src and enhance the tyrosine phosphorylation of NMDAR in the
spinal cord, which contributes to the development of diabetic neuro-
pathy [39]. Moreover, the siRNA-mediated knockdown of PTP1B or a
PTP inhibitor represses Src activity and reverses mechanical allodynia
in STZ-injected rats. These ﬁndings demonstrate that Src/GluN2B sig-
nalling represents a vital pathway through which PTP1B exaggerates
painful responses. The present studies also conﬁrm the activation of
spinal microglia in STZ-injected rats, not only through alterations in
morphology but also through the activation of intracellular signalling
involved in microglia functions. As shown by Tsuda et al., the SFK/ERK
signalling pathway is implicated in the process of microglial activation
caused by STZ injection [28]. Moreover, the intrathecal administration
of U0126, an inhibitor of ERK activation, remarkably alleviates tactile
allodynia in diabetic rats.
3.3. SFKs and cancer pain
Treating cancer pain remains a clinical challenge, and current an-
algesics may be inadequate, therefore, there is a great need for new
treatment strategies [49]. The mechanism of cancer pain may consist of
components of both neuropathic and inﬂammatory pain but also in-
volve distinctive characteristics [50]. In this review, we focus on the
role of SFKs in pain caused by bone metastasis. There are several factors
that contribute to the development of bone cancer pain, including da-
mage to the surrounding nerves and tissue, release of inﬂammatory
mediators, injury to sensory nerve ﬁber terminals and increased bone
degradation [19]. Src, a non-receptor protein tyrosine kinase, is in-
volved in several processes that lead to bone cancer pain, such as cancer
growth, angiogenesis and metastasis [19]. Src is widely expressed in
osteoclasts, platelets, and neurons [51]. Regarding pain pathologies, it
has been widely demonstrated that the activation of Src contributes to
bone cancer pain through the phosphorylation of the NMDARs. As
shown by Liu et al., the spinal administration of recombinant IL-18 to
naïve rats can induce pain hypersensitivity, and the activation of
GluN2B [4]. Furthermore, the Src inhibitor PP1 remarkably inhibits IL-
18-induced GluN2B. Moreover, Src is also a key regulator of bone re-
sorption. Mice lacking the Src gene develop osteopetrosis, mainly due
to impaired osteoclastic function. It has been reported that a Src in-
hibitor can reduce pain hypersensitivity in bone cancer pain rats, and
that this eﬀect is associated with both a reduction of NMDAR activity
and the inhibition of bone resorption [51].
3.4. SFKs and morphine tolerance
Tolerance of the eﬀects of opioid analgesics is a major clinical issue
in chronic pain treatment due to the poor understanding of its core
mechanisms [52]. A recent study demonstrated that morphological
changes in opioid receptors, and the activation of NMDARs are im-
plicated in the development of opioid tolerance [53]. The μ-opioid re-
ceptor (MOR) mediates both the beneﬁcial and adverse eﬀ ;ects of
opioids [54,55]. It is worth noting that β-Arrestin2, a protein that re-
cruits c-Src to MORs, is critical for the development of morphine tol-
erance [56]. Additionally, β-arr 2−/− mice exhibit upregulate MOR-
mediated basal nociception and reverse morphine tolerance. Mean-
while, the inhibition of c-Src in DRG β-arr 2+/+ neurons increases the
expression of the MOR and abolishes opioid-induced desensitization in
vitro [57]. Therefore, c-Src, which is recruited by β-arrestin2, is re-
quired for the development of morphine tolerance. It is widely known
Fig. 2. Schematic representation of the potential mechanisms by which SFKs
are involved in neuropathic pain. a) The peri-sciatic administration of re-
combinant rat IFN-γ can produce long-lasting pain hypersensitivity via activa-
tion of Lyn/P2X4R. b) GDNF can directly or indirectly regulate nectin-1/c-src
signalling, thereby mediating the synaptic remodelling process in the spinal
cord. c) The SFK/ERK signalling pathway is implicated in the process of mi-
croglial activation in STZ-injected rats. d) PTP1B can stimulate Src and enhance
the tyrosine phosphorylation of NMDAR in the spinal cord, contributing to the
development of diabetic neuropathy. BDNF: brain-derived neurotrophic factor;
ERK: extracellular signal-related kinase; GDNF: glial cell line-derived neuro-
trophic factor; GFRα1: glial cell line-derived neurotrophic factor receptor α 1;
IFN-γ: interferon-γ; IFN-γR: IFN-γ receptor; NMDAR: N-methyl-D-aspartate re-
ceptor; PTP1B: Protein tyrosine phosphatase 1B; P2X4R: P2X4 receptor; SFKs:
Src-family protein tyrosine kinases; STZ: streptozotocin.
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that NMDARs have a well-developed role in neural plasticity and var-
ious pain states [18,51]. Multiple groups have also demonstrated the
functional cross-regulation between MORs and NMDARs. Opioids, such
as morphine, can disrupt the interaction between MORs and NMDARs
and activate NMDARs via PKC/Src, which contributes to the develop-
ment of morphine tolerance [58].
Activated microglia have also been involved in the regulation of
morphine tolerance. Furthermore, the injection of minocycline (a se-
lective microglial inhibitor) has been reported to reverse the develop-
ment of morphine tolerance [59]. Although the mechanisms by which
microglia regulates morphine tolerance are largely unknown, the acti-
vation of P2X7 receptors (P2X7Rs) and MAPK has been speciﬁcally
implicated in the initiation and development of morphine tolerance
[53]. In addition, Leduc-Pessah et al. found that morphine potentiates
P2X7R-mediated Ca2+ responses in spinal microglia [52]. Moreover,
increased P2X7R function is reversed by the SFKs inhibitor PP2 in
cultured microglia. The researchers found that Src is a potential in-
tracellular mediator of P2X7Rs and that its activation by morphine
likely participates in the development of morphine tolerance. Chemo-
kines, a superfamily of small proteins, play a crucial role in immune and
neuromodulatory functions [60,61]. Recently, several studies reported
that the activation of cognate G protein-coupled receptor (CXCR4) by
exogenous chemokine CXC motif ligand 12 (CXCL12) can activate the
SFK signalling pathway in sensory neurons in the DRG and microglia in
the spinal cord [53,62]. Thus, the activation of SFKs induced by the
administration of CXCL12 is also consistent with the regulatory role of
microglia in morphine tolerance.
4. Conclusions
In this review, we summarized the cellular and molecular
mechanisms of the role of SFKs in the initiation and development of
chronic pain and morphine tolerance (Figs. 3). SFKs are critical for
various cellular signalling pathways that promote pain hypersensitivity,
suggesting that aberrant SFK activity may be a potential therapeutic
target for the management of chronic pain [36,56,63]. Furthermore,
increased SFK activity is also associated with the processes of bone
resorption, tumor growth, and metastasis in vitro and in vivo [19].
Recent advances in our understanding of the role of SFKs in preclinical
studies have laid a foundation for the clinical application of SFK in-
hibitors (such as dasatinib and saracatinib) for the treatment of tu-
morigenesis, bone metastasis and chronic pain [19,64]. Emerging
clinical data suggest that SFK inhibitors have the potential to inhibit
cancer-related bone resorption and metastasis [65,66]. However, few
clinical trials have studied SFK inhibitors for the treatment of chronic
pain. Although the clinical value of SFK inhibitors for the treatment of
chronic pain has not yet been clearly determined, preclinical studies of
SFKs will ultimately provide the proper groundwork for drug devel-
opment and clinical trials for pain therapies. Therefore, future extensive
exploratory studies and clinical trials should be performed with more
selective and clinically relevant drugs targeting SFKs.
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